Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WES-based phase II basket trial of durvalumab + tremelimumab in high tumor mutational burden metastatic solid tumors
2018-003115-21Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Feb 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in colorectal adenocarcinoma, triple-negative breast cancer (TNBC), prostate adenocarcinoma and 3 more, sponsored by Gustave Roussy. Primary endpoint: Objective tumour response rate. Started Feb 2019; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal adenocarcinomatriple-negative breast cancer (TNBC)prostate adenocarcinomagastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-003115-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003115-21.